[HTML][HTML] 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2023

NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2023 - ncbi.nlm.nih.gov
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023

NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2023 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021

American Diabetes Association - Diabetes care, 2021 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
the ADA's current clinical practice recommendations and is intended to provide the …

The predictive approaches to treatment effect heterogeneity (PATH) statement

DM Kent, JK Paulus, D Van Klaveren… - Annals of internal …, 2020 - acpjournals.org
Heterogeneity of treatment effect (HTE) refers to the nonrandom variation in the magnitude
or direction of a treatment effect across levels of a covariate, as measured on a selected …

10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020

American Diabetes Association - Diabetes care, 2020 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
the ADA's current clinical practice recommendations and is intended to provide the …

10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019

American Diabetes Association - Diabetes care, 2019 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
ADA's current clinical practice recommendations and is intended to provide the components …

Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects

DM Kent, E Steyerberg, D Van Klaveren - Bmj, 2018 - bmj.com
The use of evidence from clinical trials to support decisions for individual patients is a form of
“reference class forecasting”: implicit predictions for an individual are made on the basis of …

10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022

American Diabetes Association Professional … - Diabetes …, 2022 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
the ADA's current clinical practice recommendations and is intended to provide the …

Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison

MD Kelsey, AJ Nelson, JB Green, CB Granger… - Journal of the American …, 2022 - jacc.org
Cardiovascular disease is a leading cause of morbidity and mortality in individuals with type
2 diabetes mellitus. These high-risk patients benefit from aggressive risk factor …

Inhaled corticosteroids in COPD: friend or foe?

A Agusti, LM Fabbri, D Singh, J Vestbo… - European …, 2018 - Eur Respiratory Soc
The efficacy, safety and positioning of inhaled corticosteroids (ICS) in the treatment of
patients with chronic obstructive pulmonary disease (COPD) is much debated, since it can …